The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1285
Ciclesonide (Omnaris) for Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ciclesonide (Omnaris – Sepracor/Nycomed), a once-daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter.

PHARMACOLOGY — Ciclesonide is a prodrug that is hydrolyzed to des-ciclesonide, a pharmacologically active metabolite, by esterases in the nasal mucosa.

CLINICAL STUDIES — Ciclesonide nasal spray 200 mcg once daily was superior to placebo in adults and adolescents with SAR treated for 2 weeks or PAR treated for 6 weeks, with significant reductions in nasal symptom scores of 27% and 33% from baseline compared to reductions of 17% ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ciclesonide (Omnaris) for Allergic Rhinitis
Article code: 1285a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian